Recent legislative and regulatory events, including the potential rescheduling from Schedule I to Schedule III and the SAFER Banking Act, are leading to a dramatic shift in the cannabis industry, with a particular impact on cannabinoid research.

MARCO ISLAND, Florida—World-renowned cannabis expert Ethan Russo, MD, says the industry he loves is in serious trouble. Although [cannabidiol] (CBD) is “a remarkable and versatile compound,” he said, it comes with severe limitations: As an isolate, very high dosages are needed. It does not work well on its own and its high cost makes access…

In a historic decision, the US Department of Health and Human Services recommended rescheduling marijuana to Schedule III.

Margaret Haney, PhD, speaks to conference attendees at Columbia University in New York City. New York, NY—Vast changes in cannabis public policy have occurred over the past 20 years with little scientific input, Margaret Haney, PhD, told attendees at the inaugural meeting of Medical Cannabis: The Science. The Research. The Risks, held at Columbia University.1…

A joint venture has been formed between Charlotte’s Web Holdings, Inc. (CW) and AJNA Biosciences PBC (ANJA), a subsidiary of British American Tobacco PLC (BAT), to pursue FDA approval for a new botanical hemp product designed to address a neurological condition. The venture, announced via news release, will be led by neurologist Orrin Devinsky, MD,…

As of July 1, 2023, the Australian government’s Therapeutic Goods Administration (TGA) will allow authorized psychiatrists to prescribe 3,4-methylenedioxy-methamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD). The permission, announced via news release, involves changing the classification of these drugs in the Poisons Standard from Schedule 9 (Prohibited Substances) to Schedule…